Last reviewed · How we verify
Rimegepant 75mg every other day dosing (rimegepant-75mg-every-other-day-dosing)
Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines.
Rimegepant, a 75mg every other day dosing drug developed by Pfizer, holds a significant market position with $798M in revenue, making it one of the leading treatments for migraines. Despite its strong market presence, Rimegepant faces competition from drugs like Candesartan, Telmisartan, Erenumab, Fremanezumab, and Galcanezumab, which have stronger guideline support for episodic migraine prevention. A key risk for Rimegepant is the lack of ongoing clinical trials, which may limit future evidence and regulatory support. The pipeline outlook remains uncertain due to the absence of new clinical trials and the requirement for a PD-L1 companion diagnostic for several indications.
At a glance
| Generic name | rimegepant-75mg-every-other-day-dosing |
|---|---|
| Sponsor | Pfizer |
| Drug class | calcitonin gene-related peptide receptor antagonist |
| Target | calcitonin gene-related peptide receptor |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| Annual revenue | 798 |
Mechanism of action
Rimegepant works by binding to the calcitonin gene-related peptide receptor, which is involved in the pathophysiology of migraines. This binding action helps to reduce the frequency and severity of migraine attacks. By targeting this specific receptor, rimegepant offers a unique approach to treating migraines compared to other medications.
Approved indications
- Acute treatment of migraine attacks with or without aura in adults
- Prevention of migraine attacks in adults
Common side effects
- Nasopharyngitis
- COVID-19
Drug interactions
- Warfarin
- P-glycoprotein inhibitors (e.g., cyclosporine, ketoconazole)
- P-glycoprotein inducers (e.g., rifampin, St. John's Wort)
- Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)
- Strong CYP3A4 inducers (e.g., rifampin, St. John's Wort)
- CYP3A4 substrates (e.g., midazolam, simvastatin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimegepant 75mg every other day dosing CI brief — competitive landscape report
- Rimegepant 75mg every other day dosing updates RSS · CI watch RSS
- Pfizer portfolio CI